BB BIOTECH AG
· ISIN: CH0038389992
· EQS - Company News
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News BB BIOTECH AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
19 March 2025 05:45PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
Media release of March 19, 2025
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.
Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
21 February 2025 07:00AM
BB Biotech AG publishes its 2024 annual report
Ad hoc announcement pursuant to Art. 53 LR
February 21, 2025
Annual report of BB Biotech AG as at December 31, 2024
BB Biotech AG publishes its 2024 annual report
BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
21 February 2025 07:00AM
BB Biotech positions for structural sector recovery amid shifting market dynamics
Media release as at February 21, 2025
Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics
2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commercial execution.
BB Biotec...
BB BIOTECH AG
24 January 2025 07:00AM
Preliminary full-year 2024 results and dividend proposal
Media release as of January 24, 2025
BB Biotech: Preliminary full-year 2024 results and dividend proposal
BB Biotech AG reports the following preliminary and unaudited figures for 2024:
Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV performan...
BB BIOTECH AG
24 January 2025 07:00AM
BB Biotech AG closes the 2024 fiscal year with a profit
Ad hoc announcement pursuant to Art. 53 LR
January 24, 2025
BB Biotech AG closes the 2024 fiscal year with a profit
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information:
Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately...
BB BIOTECH AG
22 January 2025 02:31PM
Edison issues report on BB Biotech (BION)
London, UK, 22 January 2025
Edison issues report on BB Biotech (BION)
Edison issues report on BB Biotech (BION).
BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative d...
Edison Investment Research Limited
25 October 2024 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
October 25, 2024
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2024, which covers the results of its business activities for the first nine months of 2024.
Based on the consolidated accounts of BB Biotech AG, net prof...
BB BIOTECH AG
25 October 2024 07:00AM
Strategic reallocation of portfolio assets progressing
Media release as at October 25, 2024
Portfolio of BB Biotech AG as at September 30, 2024
BB Biotech: Strategic reallocation of portfolio assets progressing
In the third quarter of 2024, stock markets remained volatile. The recent rate cut by the US central bank has improved the market dynamics for the biotechnology sector because lower interest ...
BB BIOTECH AG
23 October 2024 10:12AM
Edison issues report on BB Biotech (BION)
London, UK, 23 October 2024
Edison issues report on BB Biotech (BION)
Edison issues report on BB Biotech (BION).
BB Biotech (BION) invests in innovative, rapidly expanding biotech companies. BION’s portfolio company Wave Life Sciences (Wave) recently announced a significant milestone in the field of genetic medicine: the first successful t...
Edison Investment Research Limited
26 July 2024 07:00AM
BB Biotech AG publishes its interim report and announces a new head of its investment management team
Ad hoc announcement pursuant to Art. 53 LR
July 26, 2024
BB Biotech AG publishes its interim report and announces a new head of its investment management team
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2024, which covers the results of its business activities for the first six months of 2024.
Based on th...
BB BIOTECH AG
26 July 2024 07:00AM
Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
Media release as at July 26, 2024
Portfolio of BB Biotech AG as at June 30, 2024
Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
Global equity indices climbed to new record highs during the second quarter, driven by just a few mega tech stocks, but investors continued to shun the healthcare sec...
BB BIOTECH AG
26 June 2024 02:08PM
Edison issues report on BB Biotech (BION)
London, UK, 26 Juni 2024
Edison issues report on BB Biotech (BION)
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not...
Edison Investment Research Limited
20 May 2024 12:53PM
A recovering sector with a healthy prognosis
London, UK, 20 May 2024
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial...
Edison Investment Research Limited
26 April 2024 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
April 26, 2024
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2024, which covers the results of its business activities for the first three months of 2024.
Based on the consolidated accounts of BB Biotech AG, net profit fo...
BB BIOTECH AG
26 April 2024 07:00AM
BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
Media release as at April 26, 2024
Portfolio of BB Biotech AG as at March 31, 2024
BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
Investor sentiment in the biotech space continues to be shaped by the general interest rate environment. Biotechnology stocks traded higher early in ...
BB BIOTECH AG
21 March 2024 06:00PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
Media release of March 21, 2024
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.
Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
16 February 2024 07:00AM
BB Biotech AG publishes its 2023 annual report
Ad hoc announcement pursuant to Art. 53 LR
February 16, 2024
Annual report of BB Biotech AG as at December 31, 2023
BB Biotech AG publishes its 2023 annual report
BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
14 February 2024 07:00AM
Investor interest returns – dividend yield remains high for 2024
Release as at February 14, 2024Investor interest returns – dividend yield remains high for 2024
After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of falling interest rates has led to a rethink. While the majority of inves...
BB BIOTECH AG
19 January 2024 07:00AM
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
Ad hoc announcement pursuant to Art. 53 LR
January 19, 2024
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information:
Results for the financial year 2023
Based on its preliminary unaudited ...
BB BIOTECH AG
19 January 2024 07:00AM
End of year biotech equity market rally – M&A and end of rate hike cycle
Media release as at January 19, 2024
Portfolio of BB Biotech AG as at December 31, 2023
End of year biotech equity market rally – M&A and end of rate hike cycle
In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in a year-end bond ma...
BB BIOTECH AG
20 October 2023 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
October 20, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2023, which covers the results of its business activities for the first nine months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss...
BB BIOTECH AG
20 October 2023 07:00AM
the impact of rising bond yields and shifting healthcare policies
Media release as at October 20, 2023
Interim report of BB Biotech AG as at September 30, 2023
Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
Expectations that the US central bank would soon reverse its monetary policy stance proved to be premature. The rise in bond yields weighed heavily on biot...
BB BIOTECH AG
21 July 2023 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
July 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2023, which covers the results of its business activities for the first six months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
21 July 2023 07:00AM
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
Media release as at July 21, 2023
Interim report of BB Biotech AG as at June 30, 2023
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
The first half of 2023 has been disappointing for biotech investors. A massive rotation has put biotech stocks under pressure. Whereas...
BB BIOTECH AG
21 July 2023 07:00AM
BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
Media release as at July 21, 2023
Interim report of BB Biotech AG as at June 30, 2023
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
The first half of 2023 has been disappointing for biotech investors. A massive rotation has put biotech stocks under pressure. Whereas...
BB BIOTECH AG
21 July 2023 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
July 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2023, which covers the results of its business activities for the first six months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
03 May 2023 07:00AM
Creating blockbuster drugs using algorithms
Expert commentary
Creating blockbuster drugs using algorithms
Artificial intelligence is becoming an increasingly important tool in the drug discovery and development process. Biotech investors benefit from this technology too.
Dr. Samuel Croset, Data Scientist BB Biotech at Bellevue Asset Management
Artificial intelligence and machine-learning...
BB BIOTECH AG
03 May 2023 07:00AM
BB BIOTECH AG: Creating blockbuster drugs using algorithms
Expert commentary
Creating blockbuster drugs using algorithms
Artificial intelligence is becoming an increasingly important tool in the drug discovery and development process. Biotech investors benefit from this technology too.
Dr. Samuel Croset, Data Scientist BB Biotech at Bellevue Asset Management
Artificial intelligence and machine-learning...
BB BIOTECH AG
21 April 2023 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
April 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for ...
BB BIOTECH AG
21 April 2023 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
April 21, 2023
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023.
Based on the consolidated accounts of BB Biotech AG, net loss for ...
BB BIOTECH AG
21 April 2023 07:00AM
Lackluster first quarter for biotech stocks
Media release as at April 21, 2023
Interim report of BB Biotech AG as at March 31, 2023
Lackluster first quarter for biotech stocks
Concerns about capital market resilience clearly had an impact on investor preferences during the first quarter. After a strong start to the year, market sentiment switched to risk-off and this triggered heavy sellin...
BB BIOTECH AG
21 April 2023 07:00AM
BB BIOTECH AG: Lackluster first quarter for biotech stocks
Media release as at April 21, 2023
Interim report of BB Biotech AG as at March 31, 2023
Lackluster first quarter for biotech stocks
Concerns about capital market resilience clearly had an impact on investor preferences during the first quarter. After a strong start to the year, market sentiment switched to risk-off and this triggered heavy sellin...
BB BIOTECH AG
23 March 2023 05:45PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Media release of March 23, 2023
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.
Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
23 March 2023 05:45PM
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Media release of March 23, 2023
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.
Shareholders voted in favor of the proposal to pay out a divi...
BB BIOTECH AG
17 February 2023 07:00AM
BB Biotech AG publishes its 2022 annual report
Ad hoc announcement pursuant to Art. 53 LR
February 17, 2023
Annual report of BB Biotech AG as at December 31, 2022
BB Biotech AG publishes its 2022 annual report
BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
17 February 2023 07:00AM
BB Biotech AG publishes its 2022 annual report
Ad hoc announcement pursuant to Art. 53 LR
February 17, 2023
Annual report of BB Biotech AG as at December 31, 2022
BB Biotech AG publishes its 2022 annual report
BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi...
BB BIOTECH AG
20 January 2023 07:00AM
BB Biotech AG closes the 2022 fiscal year with a loss
Ad hoc announcement pursuant to Art. 53 LR
January 20, 2023
BB Biotech AG closes the 2022 fiscal year with a loss
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2022.
Based on its preliminary unaudited consolidated figures, BB ...
BB BIOTECH AG
20 January 2023 07:00AM
Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
Media release as at January 20, 2023
Portfolio of BB Biotech AG as at December 31, 2022
Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
The year 2022 saw volatile market conditions for global equity and bond markets, with substantial stepwise increases in central bank rates, led by the US ...
BB BIOTECH AG
08 December 2022 05:00PM
BB BIOTECH AG: Molecular strike force for the immune system
Market commentary, December 8, 2022
Dr. Daniel Koller, Head of BB Biotech’s Investment Management Team at Bellevue Asset Management
Molecular strike force for the immune system
The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities.
Autoim...
BB BIOTECH AG
08 December 2022 05:00PM
Molecular strike force for the immune system
Market commentary, December 8, 2022
Dr. Daniel Koller, Head of BB Biotech’s Investment Management Team at Bellevue Asset Management
Molecular strike force for the immune system
The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities.
Autoim...
BB BIOTECH AG
21 October 2022 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
October 21, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss...
BB BIOTECH AG
21 October 2022 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
October 21, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss...
BB BIOTECH AG
21 October 2022 07:00AM
US drug pricing legislation drives biotech business to adapt for further innovation
Media release as at October 21, 2022
Interim report of BB Biotech AG as at September 30, 2022
US drug pricing legislation drives biotech business to adapt for further innovation
Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid...
BB BIOTECH AG
21 October 2022 07:00AM
BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
Media release as at October 21, 2022
Interim report of BB Biotech AG as at September 30, 2022
US drug pricing legislation drives biotech business to adapt for further innovation
Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid...
BB BIOTECH AG
30 August 2022 11:00AM
Moderna was just the beginning
Market commentary, August 30, 2022
Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management
Moderna was just the beginning
RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.
Alnylam, a stock in BB Biotech's portfolio, ...
BB BIOTECH AG
30 August 2022 11:00AM
BB BIOTECH AG: Moderna was just the beginning
Market commentary, August 30, 2022
Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management
Moderna was just the beginning
RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.
Alnylam, a stock in BB Biotech's portfolio, ...
BB BIOTECH AG
22 July 2022 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
22 July 2022 07:00AM
BB Biotech AG publishes its interim report
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the ...
BB BIOTECH AG
More BB BIOTECH AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 7 | 7th March 2025 | von Planta, Dr. Thomas | DD |
| Short Seller (DE) | 1 | 15th December 2016 | Elliott Capital Advisors, L.P. | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN